BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRXBiotechnology
+$0.09 today
- Market cap
- $1.88B
- Beta
- 0.56
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.89
Volume 2.95M
Average 4.85M
BCRX Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue grows, but more slowly than its trailing trend
Q2 FY2026 revenue of $218.25M rose 33.6% year over year, behind the +68.7% change in trailing-twelve-month revenue. Sequentially, it rose 39.5% from the prior quarter. Over 3 fiscal years it compounded at +47.8% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 7 analysts of $718.73M (-17.8%) for the fiscal year ending Dec 2026, a slowdown from the +94.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $218.25M+39.5% QoQ
- Last fiscal yearDec 2025
- $874.84M+94.1% YoY
- LTMJun 2026
- $940.61M+68.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +33.6% | +3.9% | -29.7 pp |
| 1 year | +94.1% | -17.8% | -111.9 pp |
| 3-year CAGR | +47.8% | -2.5% | -50.3 pp |
| 5-year CAGR | +4.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 874.84M USD
- Year-over-year change
- +94.1%
- 4-year CAGR
- +53.6%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 874.84M | +94.1% |
| FY2024 | 2024-12-31 | 450.71M | +36.0% |
| FY2023 | 2023-12-31 | 331.41M | +22.4% |
| FY2022 | 2022-12-31 | 270.83M | +72.3% |
| FY2021 | 2021-12-31 | 157.17M | — |
Revenue vs competitors
How BCRX compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +68.7% is the lowest of 2, against a peer median of +214.0%.
- Over three fiscal years its annual growth of +47.8% compares with a peer median of -65.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $940.61M USD | +68.7% | +47.8% | |
| LTM Mar 2026 | $65.5M USD | +214.0% | -65.1% | |
| LTM Sep 2026 | €0 EUR | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding BCRX) | — | +214.0% | -65.1% | |
Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 157.17M | 270.83M | 331.41M | 450.71M | 874.84M |
| Cost of Revenue | 7.26M | 6.59M | 4.66M | 12.49M | 19.08M |
| Gross Profit | 149.91M | 264.23M | 326.75M | 438.23M | 855.76M |
| Gross Margin | 95.4% | 97.6% | 98.6% | 97.2% | 97.8% |
| Research & Development | 208.81M | 253.3M | 216.57M | 174.64M | 166.13M |
| Selling, General & Admin | 118.82M | 159.37M | 213.89M | 266.13M | 348.65M |
| Operating Expenses | 327.63M | 412.67M | 430.46M | 440.77M | 514.77M |
| Depreciation & Amortization | 777K | 1.44M | 1.66M | 1.25M | 1.39M |
| EBITDA | (121.74M) | (143.85M) | (116.34M) | 12.81M | 347.65M |
| EBITDA Margin | -77.5% | -53.1% | -35.1% | 2.8% | 39.7% |
| Operating Income | (177.72M) | (148.44M) | (103.71M) | (2.54M) | 340.99M |
| Operating Margin | -113.1% | -54.8% | -31.3% | -0.6% | 39.0% |
| Interest Income | 62K | 5.13M | 15.78M | 14.75M | 10.67M |
| Interest Expense | 59.29M | 99.09M | 108.24M | 98.52M | 78.87M |
| Other Income / Expenses | (4.09M) | (95.95M) | (122.52M) | (84.41M) | (73.6M) |
| Income Before Tax | (181.81M) | (244.38M) | (226.23M) | (86.95M) | 267.39M |
| Pre-Tax Margin | -115.7% | -90.2% | -68.3% | -19.3% | 30.6% |
| Income Tax Expense | 2.25M | 2.73M | 310K | 1.93M | 3.53M |
| Net Income | (184.06M) | (247.12M) | (226.54M) | (88.88M) | 263.86M |
| Net Margin | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% |
| EPS (Basic) | (1.03) | (1.33) | (1.18) | (0.43) | 1.26 |
| EPS (Diluted) | (1.03) | (1.33) | (1.18) | (0.43) | 1.21 |
| Weighted Avg Shares | 179.12M | 185.91M | 192.2M | 206.7M | 209.89M |
| Weighted Avg Shares (Diluted) | 179.12M | 185.91M | 192.2M | 206.7M | 218.58M |
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
Intrinsic Alpha fair value
Locked
Current Price
$7.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.